In a decisive regulatory action, Brazil's National Health Surveillance Agency (Anvisa) has suspended manufacturing and mandated a full recall of specific products from the cleaning brand Ypê. The move targets all batches ending in the number one for detergents, liquid soaps, and disinfectants produced at the company's Química Amparo facility in the interior of São Paulo state.
The agency's intervention stems from a documented history of microbiological contamination at the plant. Back in November 2025, Ypê had voluntarily recalled certain liquid laundry detergent batches after detecting the presence of Pseudomonas aeruginosa bacteria. This prior incident set the stage for the recent, more comprehensive inspection.
The latest inspection, conducted jointly with state and municipal health authorities between April 27 and 30, 2026, uncovered significant breaches of Good Manufacturing Practices (BPF). Inspectors identified critical weaknesses in the company's quality assurance systems, quality control protocols, cleaning and sanitization procedures, and overall microbiological oversight. These failures are directly linked to preventing product contamination.
While the current enforcement action is based on the April findings, Anvisa confirmed that the November 2025 contamination case was a key factor in its risk assessment and decision to re-inspect the facility. The agency stated that the new inspection was triggered precisely because of this contamination history and new information suggesting a need to re-evaluate manufacturing conditions.
When asked about the potential health risk, Anvisa indicated that a sanitary risk was identified based on the totality of the inspection findings. The measures taken—recall, suspension of production, commercialization, distribution, and use—are characterized by the agency as preventive and proportional to the risk.
Ypê has responded with strong opposition, calling the decision "arbitrary and disproportionate." The company claims to possess robust scientific evidence from independent laboratory reports proving its products are "completely safe and adequate for consumption." It has announced plans to appeal the agency's order.
The bacterium at the center of the initial concern, Pseudomonas aeruginosa, is an opportunistic pathogen commonly found in the environment. It rarely causes illness in healthy individuals but can pose a serious threat to people with compromised immune systems, such as cancer patients, transplant recipients, or those with advanced HIV. Medical literature notes that infections can range from minor external issues to life-threatening conditions in vulnerable populations.
Based on reporting from g1.